602 related articles for article (PubMed ID: 30081936)
1. Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
Botticelli A; Cerbelli B; Lionetto L; Zizzari I; Salati M; Pisano A; Federica M; Simmaco M; Nuti M; Marchetti P
J Transl Med; 2018 Aug; 16(1):219. PubMed ID: 30081936
[TBL] [Abstract][Full Text] [Related]
2. Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1.
Botticelli A; Mezi S; Pomati G; Cerbelli B; Cerbelli E; Roberto M; Giusti R; Cortellini A; Lionetto L; Scagnoli S; Zizzari IG; Nuti M; Simmaco M; Marchetti P
Front Immunol; 2020; 11():1243. PubMed ID: 32733441
[No Abstract] [Full Text] [Related]
3. Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer.
Suzuki Y; Suda T; Furuhashi K; Suzuki M; Fujie M; Hahimoto D; Nakamura Y; Inui N; Nakamura H; Chida K
Lung Cancer; 2010 Mar; 67(3):361-5. PubMed ID: 19487045
[TBL] [Abstract][Full Text] [Related]
4. Kynurenine/Tryptophan Ratio as a Potential Blood-Based Biomarker in Non-Small Cell Lung Cancer.
Mandarano M; Orecchini E; Bellezza G; Vannucci J; Ludovini V; Baglivo S; Tofanetti FR; Chiari R; Loreti E; Puma F; Sidoni A; Belladonna ML
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922388
[TBL] [Abstract][Full Text] [Related]
5. IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients.
Wang W; Huang L; Jin JY; Jolly S; Zang Y; Wu H; Yan L; Pi W; Li L; Mellor AL; Kong FS
Cancer Res; 2018 Feb; 78(3):809-816. PubMed ID: 29118088
[TBL] [Abstract][Full Text] [Related]
6. Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase.
Iversen TZ; Engell-Noerregaard L; Ellebaek E; Andersen R; Larsen SK; Bjoern J; Zeyher C; Gouttefangeas C; Thomsen BM; Holm B; Thor Straten P; Mellemgaard A; Andersen MH; Svane IM
Clin Cancer Res; 2014 Jan; 20(1):221-32. PubMed ID: 24218513
[TBL] [Abstract][Full Text] [Related]
7. Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms.
Schefold JC; Zeden JP; Fotopoulou C; von Haehling S; Pschowski R; Hasper D; Volk HD; Schuett C; Reinke P
Nephrol Dial Transplant; 2009 Jun; 24(6):1901-8. PubMed ID: 19155537
[TBL] [Abstract][Full Text] [Related]
8. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
9. Peripheral kynurenine/tryptophan ratio is not a reliable marker of systemic indoleamine 2,3-dioxygenase: A lesson drawn from patients on hemodialysis.
Chen Y; Xie Z; Xiao C; Zhang M; Li Z; Xie J; Zhang Y; Zhao X; Zeng P; Mo L; Liang X; Shi W
Oncotarget; 2017 Apr; 8(15):25261-25269. PubMed ID: 28445957
[TBL] [Abstract][Full Text] [Related]
10. Revisiting IDO and its value as a predictive marker for anti-PD-1 resistance.
Moon PK; Tran S; Minhas PS
J Transl Med; 2019 Jan; 17(1):31. PubMed ID: 30658666
[TBL] [Abstract][Full Text] [Related]
11. Serum activity of indoleamine 2,3-dioxygenase predicts prognosis of community-acquired pneumonia.
Suzuki Y; Suda T; Yokomura K; Suzuki M; Fujie M; Furuhashi K; Hahimoto D; Enomto N; Fujisawa T; Nakamura Y; Inui N; Nakano Y; Nakamura H; Chida K
J Infect; 2011 Sep; 63(3):215-22. PubMed ID: 21784100
[TBL] [Abstract][Full Text] [Related]
12. Dynamic change of IDO1 activity predicts survival in patients with unresectable stage III NSCLC and chemoradiotherapy.
Wu L; Wang D; Chen Y; Qian M; Xu X; Zhang T; Bi N; Wang L
Front Immunol; 2022; 13():906815. PubMed ID: 36032151
[TBL] [Abstract][Full Text] [Related]
13. Serum tryptophan and kynurenine concentrations as parameters for indoleamine 2,3-dioxygenase activity in patients with endometrial, ovarian, and vulvar cancer.
de Jong RA; Nijman HW; Boezen HM; Volmer M; Ten Hoor KA; Krijnen J; van der Zee AG; Hollema H; Kema IP
Int J Gynecol Cancer; 2011 Oct; 21(7):1320-7. PubMed ID: 21720257
[TBL] [Abstract][Full Text] [Related]
14. Activation of the kynurenine pathway is associated with poor outcome in Pneumocystis pneumonia patients infected with HIV: results of 2 months cohort study.
Wang M; Dong X; Huang Y; Su J; Dai X; Guo Y; Hu C; Zhou Q; Zhu B
BMC Infect Dis; 2019 Mar; 19(1):223. PubMed ID: 30832615
[TBL] [Abstract][Full Text] [Related]
15. Mass spectrometric measurement of urinary kynurenine-to-tryptophan ratio in children with and without urinary tract infection.
Yarbrough ML; Briden KE; Mitsios JV; Weindel AL; Terrill CM; Hunstad DA; Dietzen DJ
Clin Biochem; 2018 Jun; 56():83-88. PubMed ID: 29679555
[TBL] [Abstract][Full Text] [Related]
16. Association between IDO activity and prognosis in patients with non-small cell lung cancer after radiotherapy.
Zhu Y; Jiang C; Liu Y; Li Y; Wu H; Feng J; Xu Y
Ann Transl Med; 2020 Sep; 8(18):1169. PubMed ID: 33241018
[TBL] [Abstract][Full Text] [Related]
17. High activity of indoleamine 2,3 dioxygenase enzyme predicts disease severity and case fatality in bacteremic patients.
Huttunen R; Syrjänen J; Aittoniemi J; Oja SS; Raitala A; Laine J; Pertovaara M; Vuento R; Huhtala H; Hurme M
Shock; 2010 Feb; 33(2):149-54. PubMed ID: 19487973
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of tryptophan catabolism in Hodgkin lymphoma.
Masaki A; Ishida T; Maeda Y; Ito A; Suzuki S; Narita T; Kinoshita S; Takino H; Yoshida T; Ri M; Kusumoto S; Komatsu H; Inagaki H; Ueda R; Choi I; Suehiro Y; Iida S
Cancer Sci; 2018 Jan; 109(1):74-83. PubMed ID: 29080383
[TBL] [Abstract][Full Text] [Related]
19. Canine mast cell tumour cells regulate tryptophan catabolism via the expression of indoleamine 2,3-dioxygenase.
Matsuda A; Hata A; Tanaka A; Matsuda H
Res Vet Sci; 2021 Jul; 137():159-162. PubMed ID: 33984619
[TBL] [Abstract][Full Text] [Related]
20. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity.
Wichers MC; Koek GH; Robaeys G; Verkerk R; Scharpé S; Maes M
Mol Psychiatry; 2005 Jun; 10(6):538-44. PubMed ID: 15494706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
